In the Specification

Please amend page 56, lines 26 and 27, to read as follows:

B1

PCR reactions were performed using PCR primers

5'hasm - 5'-tccaccatggcgctggtgcgcgcactc-3' (SEQ ID NO.: 6) and

Please amend page 57, lines 1 to 7, to read as follows:

fushasm3' - 3'-ctggatatcgtaattgtgctttataaagctg-5' (SEQ ID NO.: 7) and the pCR2.1 construct for each full length clone as template. PCR conditions using 475pg of pCR2.1 clone

B2

7a or 500 pg of pCR2.1 clone 14b were as follows: the reaction mixtures were heated to 95°C for 10 minutes, then thermocycled 30 times with a denaturing step of 95°C for 30 seconds, an annealing step of 52°C for 30 seconds, and then an extension step of 72°C for 1.5 minutes. Following these 30 cycles, the reactions were incubated at 72°C for 7 minutes, and stored at 4°C.

Please amend page 57, lines 20 to 25, to read as follows:

B3

hasm313mut + hasm3'mut:

5' gctccaccatgatatggacaggggatag 3' (SEQ ID NO.: 8)

5' gccactgtgctggatatcgtaattaac 3' (SEQ ID NO.: 9)

hasm396mut + hasm3'mut:

5' gctccaccatgacaaccaccatccagagtc 3' (SEQ ID NO.: 10)

5' gccactgtgctggatatcgtaattaac 3' (SEQ ID NO.: 9)

Please amend the paragraph that appears on page 60, lines 7 to 16, to read as follows:

B4

In order to determine if the NFIF protein was associated with pathologies including atherosclerosis that involve inflammation and to identify tissues that may be treated using the methods of the present invention, an immunocytochemical study was performed using a rabbit monoclonal antibody designated 99-06 directed against a peptide antigen (SKGANASNPGPFGDV) (SEQ ID NO.: 5) derived from residues 65 to 79 of the NFIF

protein. The peptide was synthesized at the 0.25 mmole scale using a solid phase methodology FMOC (9-fluorenylmethyloxycarbonyl) protection scheme in conjunction with the HOBT/HBTU activation chemistry (Fields et al., *Peptide Research*, 4:95-101 (1991)). An Applied Biosystems 433 Peptide Synthesizer running Applied Biosystems Fast-Moc coupling cycle was used for the synthesis of the peptide.

Please delete the Sequence Listing which appears on pages 65 to 70 in its entirety, and insert therefor as new pages 65 to 71 the enclosed Sequence Listing.

Please renumber the pages which contain the claims and Abstract as new pages 72 to 77.